全球微創椎體壓迫性骨折治療市場規模、份額及趨勢分析報告－產業概況及2032年預測

微創脊椎壓迫性骨折治療市場規模

• 2024 年全球微創椎體壓迫性骨折治療市場規模為291 萬美元 ，預計 到 2032 年將達到 145 萬美元，預測期內 複合年增長率為 9.10%。
• 市場成長主要受到骨質疏鬆症和脊椎損傷盛行率上升的推動，尤其是在老年人口中，這大大增加了對有效且微創的脊椎壓縮性骨折治療方案的需求
• 此外，患者和醫護人員對微創手術益處的認識日益加深，例如縮短住院時間、加快康復時間、降低併發症風險，這使得椎體增強技術（例如椎體成形術和椎體後凸成形術）成為首選治療方案。這些因素共同加速了微創椎體壓迫性骨折治療的普及，從而顯著促進了該行業的成長。

微創脊椎壓迫性骨折治療市場分析

• 微創脊椎壓迫性骨折治療，包括椎體成形術和椎體後凸成形術等手術，由於其與開放手術相比能夠緩解疼痛、恢復椎體高度、改善活動能力並縮短恢復時間，正在成為現代脊椎護理的重要解決方案
• 這些治療的需求不斷增長，主要是由於全球範圍內骨質疏鬆症相關骨折的增加、患者和醫生對微創技術的認識不斷提高，以及老年人口的不斷擴大，更容易出現脊柱退化和創傷相關的壓縮性骨折
• 北美在微創脊椎壓迫性骨折治療市場佔據主導地位，2024 年其收入份額最大，為 38.7%，這得益於先進的醫療基礎設施、更高的醫療支出以及創新脊椎外科技術的快速採用
• 預計亞太地區將成為微創椎體壓迫性骨折治療市場成長最快的地區，2025 年至 2032 年的複合年增長率為 10.8%。推動這一成長的因素包括老年人口的增加、骨質疏鬆症發病率的上升，以及中國、印度和韓國等新興市場優質醫療服務機會的增多
• 球囊後凸成形術在微創椎體壓迫性骨折治療市場佔據主導地位，2024 年的市佔率為 47.6%，這得益於不僅能夠穩定骨折，還能恢復椎體高度並減少後凸畸形。球囊後凸成形術的臨床優勢以及在醫院和門診日益增長的市場偏好，使其在市場上佔據領先地位。

報告範圍和微創脊椎壓迫性骨折治療市場細分   

微創脊椎壓迫性骨折治療市場趨勢

“成像和導航技術的進步”

• 全球微創椎體壓迫性骨折治療市場的一個關鍵新興趨勢是先進成像和導航系統的集成，這顯著提高了手術準確性和患者預後。這些技術使外科醫生能夠以最小的組織損傷進行精準、有針對性的干預，從而縮短恢復時間並減少併發症。
  • 例如，在椎體成形術和椎體後凸成形術過程中使用 3D 透視和即時 CT 導航可以增強骨折部位的可視化，從而更準確地放置骨水泥和植入物。
• 領先的製造商正在投資開發將這些成像技術與機器人輔助相結合的解決方案，以進一步提高手術精度。增強的影像功能還支援個人化治療計劃，使醫生能夠根據個別患者的解剖結構和骨折特徵量身定制干預措施。這降低了手術相關風險，並提高了整體臨床成功率。
• 此外，術中導航工具的整合簡化了複雜的手術，使更廣泛的醫療保健提供者（包括社區醫院和門診的醫療保健提供者）更容易接受微創椎體壓迫性骨折治療
• 這種對技術驅動的精準度和改善患者體驗的關注正在促進微創脊椎壓縮性骨折治療市場的快速增長，特別是在老齡化人口和越來越多地獲得先進醫療基礎設施的地區

微創脊椎壓迫性骨折治療市場動態

司機

“人口老化和對微創手術的需求不斷增長”

• 椎體壓迫性骨折的發生率不斷上升，尤其是在患有骨質疏鬆症的老年族群中，這是微創椎體壓迫性骨折治療需求增加的主要原因。患者和醫護人員都在尋求能夠縮短復原時間並最大限度降低手術風險的治療方案。
  • 例如，2024年初，美敦力和史賽克等公司推出了增強型椎體後凸成形術器械，旨在提高手術效率和患者舒適度，這表明行業正朝著更加患者友好的解決方案邁進。預計此類創新將在預測期內推動市場擴張。
• 人們越來越意識到微創手術的好處，例如與傳統開放式手術相比，住院時間更短、併發症發生率更低，這促使其在已開發和新興醫療市場中得到更廣泛的應用
• 此外，配備尖端成像和導航技術的先進治療中心越來越多，有助於更廣泛地獲得這些療法，從而提高不同患者群體的治療效果
• 隨著患者和醫療保健系統尋求經濟高效的治療方案，門診手術和當天出院的趨勢也推動了需求

克制/挑戰

“有限的報銷政策和程序風險”

• 儘管微創脊椎骨折治療具有臨床益處，但有限的保險報銷和不同的保險政策在某些地區對市場成長構成了重大障礙。患者可能面臨高昂的自付費用，這可能會阻礙其普及，尤其是在價格敏感的市場。
• 此外，儘管這些治療的侵入性較低，但諸如骨水泥滲漏、感染或神經損傷等風險仍然存在，這可能會引起患者和醫護人員的猶豫。儘管技術不斷進步，但對手術併發症的擔憂仍可能減緩人們對這些治療的接受度。
• 解決報銷難題需要持續的宣傳和臨床證據來證明成本效益和改善病患治療效果，而企業和醫療機構正在積極追求這些目標
• 制定臨床醫生培訓計劃和完善程序指南也在降低風險和提高對這些治療的信心方面發揮著至關重要的作用
• 透過創新和更廣泛的保險接受度來降低治療成本對於推動更廣泛的採用和維持長期市場成長至關重要

微創脊椎壓迫性骨折治療市場範圍

市場根據技術和最終用途進行細分。

• 依技術

根據技術，微創椎體壓迫性骨折治療市場細分為球囊後凸成形術和椎體成形術。球囊後凸成形術在2024年佔據最大的市場份額，達到47.6%，這得益於其與傳統方法相比，能夠更有效地恢復椎體高度並減輕疼痛。

椎體成形術領域預計將成為成長最快的領域，預計 2025 年至 2032 年的複合年增長率約為 8.5%，這得益於其成本效益以及在各種醫療保健環境中的廣泛適用性。

• 依最終用途

根據最終用途，微創椎體壓迫性骨折治療市場可細分為醫院、門診手術中心 (ASC) 和創傷中心。醫院憑藉先進的基礎設施和專業的醫護人員，在 2024 年佔據市場主導地位，收入份額將達到 65%。

預計2025年至2032年間，門診手術中心將成為成長最快的細分市場，預測期內的複合年增長率約為9.2%，這得益於人們對門診手術和經濟高效的醫療服務的日益偏好。創傷中心的市佔率保持穩定，但成長速度適中。

微創脊椎壓迫性骨折治療市場區域分析

• North America leads the minimally invasive vertebral compression fracture treatments market with the highest revenue contribution of 38.7% in 2024, driven by increasing healthcare infrastructure development and rising patient awareness about advanced spinal care options
• The region benefits from well-established healthcare facilities and a high number of specialists skilled in minimally invasive procedures, supporting widespread adoption
• Factors such as favorable reimbursement policies, growing geriatric population, and increased prevalence of osteoporosis and related spinal fractures further boost demand for these treatments in both hospital and outpatient settings

U.S. Minimally Invasive Vertebral Compression Fracture Treatments Market Insight

The U.S. minimally invasive vertebral compression fracture treatments market captured the largest revenue share within North America, often accounting for a substantial portion of the regional market. This dominance is primarily fueled by the high prevalence of osteoporosis among the aging population, leading to an increasing incidence of vertebral compression fractures (VCFs). A well-established healthcare infrastructure, high patient awareness of advanced treatment options such as vertebroplasty and kyphoplasty, and favorable reimbursement policies for these procedures further propel the market. Continuous advancements in surgical techniques and device technology also contribute significantly to the market's expansion in the U.S.

Europe Minimally Invasive Vertebral Compression Fracture Treatments Market Insight

The Europe minimally invasive vertebral compression fracture treatments market is projected to expand at a substantial CAGR during the forecast period of 2025 to 2032. This growth is primarily driven by an aging population susceptible to osteoporosis-related fractures, coupled with increasing adoption of minimally invasive techniques for pain relief and functional restoration. Stringent quality standards for medical devices and a rising focus on reducing hospital stays are fostering the adoption of these less invasive procedures. European healthcare systems are increasingly emphasizing cost-effective and patient-friendly solutions, leading to greater prescription and utilization of minimally invasive VCF treatments.

U.K. Minimally Invasive Vertebral Compression Fracture Treatments Market Insight

The U.K. minimally invasive vertebral compression fracture treatments market is anticipated to grow at a noteworthy CAGR during the forecast period of 2025 to 2032. This growth is driven by the escalating prevalence of osteoporosis among the aging population and a strong emphasis on improved patient outcomes within the National Health Service (NHS). In addition, rising awareness among both patients and healthcare providers regarding the benefits of percutaneous vertebroplasty and kyphoplasty, such as reduced pain and faster recovery, is encouraging the exploration of advanced therapeutic options. The UK’s robust healthcare infrastructure, alongside ongoing research into spinal conditions, is expected to continue to stimulate market growth.

Germany Minimally Invasive Vertebral Compression Fracture Treatments Market Insight

The Germany minimally invasive vertebral compression fracture treatments market is expected to expand at a considerable CAGR during the forecast period of 2025 to 2032. This growth is fueled by increasing awareness of spinal disorders and the demand for effective, well-tolerated treatment solutions that ensure rapid patient recovery. Germany’s well-developed healthcare system, combined with its emphasis on innovation and high-quality patient care, promotes the adoption of advanced minimally invasive VCF therapies, particularly in specialized spine clinics and hospitals. The integration of advanced imaging guidance and sophisticated bone cement delivery systems is becoming increasingly prevalent, aligning with local patient expectations for secure, patient-focused solutions.

Asia-Pacific Minimally Invasive Vertebral Compression Fracture Treatments Market Insight

The Asia-Pacific minimally invasive vertebral compression fracture treatments market is poised to grow at the fastest CAGR of 10.8% during the forecast period of 2025 to 2032. This rapid expansion is driven by increasing urbanization, rising disposable incomes, and improving healthcare access in countries such as China, Japan, and India. The region's growing aging population, coupled with increasing awareness of osteoporosis and VCFs, supported by government initiatives promoting public health, is driving the adoption of minimally invasive VCF therapies. Furthermore, as APAC's medical device manufacturing capabilities expand, the affordability and accessibility of these treatment options are reaching a wider patient base.

Japan Minimally Invasive Vertebral Compression Fracture Treatments Market Insight

The Japan minimally invasive vertebral compression fracture treatments market is gaining momentum due to the country’s significantly aging population, high healthcare spending, and a strong demand for advanced medical solutions to manage age-related conditions. The Japanese market places a significant emphasis on addressing chronic conditions such as osteoporosis. The adoption of minimally invasive VCF treatments is driven by the increasing incidence of vertebral fractures and a preference for procedures that offer quick recovery and improved quality of life. The integration of novel techniques and devices, along with robust research and development activities, is likely to spur demand for more effective and specialized access solutions in both hospital and specialty care sectors throughout the forecast period of 2025 to 2032.

China Minimally Invasive Vertebral Compression Fracture Treatments Market Insight

The China minimally invasive vertebral compression fracture treatments market accounted for the largest market revenue share in Asia Pacific in 2024, driven by the country's rapidly aging population, increasing awareness of osteoporosis, and substantial investments in healthcare infrastructure. China stands as a large and expanding market for medical devices, and minimally invasive VCF therapies are becoming increasingly popular due to their efficacy and reduced recovery times. The push towards improved healthcare access, coupled with the availability of advanced minimally invasive VCF options and the strong presence of domestic manufacturers and a growing medical device sector, are key factors propelling the market in China during the forecast period of 2025 to 2032.

Minimally Invasive Vertebral Compression Fracture Treatments Market Share

The minimally invasive vertebral compression fracture treatments industry is primarily led by well-established companies, including:

• ATEC Spine, Inc. (U.S.)
• IZI Medical Products (U.S.)
• Globus Medical (U.S.)
• Johnson & Johnson Services, Inc. (U.S.)
• Medtronic (Ireland)
• Merit Medical Systems (U.S.)
• Spine Wave, Inc. (U.S.)
• Spirit Spine Holding Corporation Inc. (Taiwan)
• Stryker (U.S.)
• Zimmer Biomet (U.S.)
• Joimax GmbH (Germany)
• Joline (Germany)
• Cigna Healthcare (U.S.)
• Lindare Medical Ltd. (U.K.)
• PanMed UAE (U.S.)
• ZAVATION (U.S.)
• Spinal Elements, Inc. (U.S.)

Latest Developments in Global Minimally Invasive Vertebral Compression Fracture Treatments Market

• In April 2023, Orthofix Medical Inc., a U.S.-based medical device company, introduced two new access retractor systems, the Lattus Lateral Access System and the Fathom Pedicle-Based Retractor System. These systems are designed to assist surgeons in minimally invasive spine (MIS) procedures, enhancing surgical workflow, improving visualization, and complementing Orthofix's comprehensive procedural solutions for conditions including vertebral compression fractures
• In March 2023, research on innovative minimally invasive implants for osteoporotic vertebral compression fractures (OVCFs) gained traction, with studies highlighting new implants such as StaXx FX, Vertebral Body Stenting, Vesselplasty, Sky Bone Expander, Kiva, Spine Jack, Osseofix, Optimesh, Jack, and V-strut. These advancements aim to overcome the limitations of traditional procedures such as vertebroplasty and kyphoplasty by improving endplate reduction and reducing complications such as cement leakage and adjacent vertebral fractures
• In 2023, significant technological advancements continued to drive the vertebroplasty and kyphoplasty devices market. These innovations include improved biomaterial-based implants designed for higher strength and reduced cement leakage, and enhanced usability for easier procedures. Product developers are increasingly focusing on affordability and ease of utility to meet the rising demand for effective, minimally invasive care for spine fractures
• In September 2022, RevBio was awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health. This grant is enabling the company to further develop its patented bone adhesive technology, Tetranite, for the treatment of vertebral compression fractures, indicating ongoing research and development into novel biomaterial solutions for VCF management

SKU-46169